The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: Evolution over a 10-year period

European Heart Journal

Volumn 26, Issue 21, 2005, Pages 2251-2258

  Shamagian, Lilian Grigorian ^a   Gonzalez Juanatey, Jose Ramon ^a   Varela Roman, Alfonso ^a   Garcia Acuña, Jose Maria ^a   Lamela, Alejandro Virgós ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

Evolution of the prognosis; Heart failure; Left ventricular systolic function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST; DISEASE COURSE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SPAIN; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

AGED; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; PREVALENCE; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 27544507282     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi383     Document Type: Article

References (32)

1. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. CHARM Investigators and Committees. Effects of candersartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
2. The Cardiac Insufficiency Bisoprolol Study II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community. A study of all incident cases in Olmsted Country, Minnesota in 1991. Circulation 1998;98:2282-2289.
4. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
5. Permanyer Miralda G, Soriano N, Brotons C, Moral I, Pinar J, Cascant P, Ribera A, Morlans M, Soler-Soler J. Baseline characteristics and determinants of outcomes in a patient population admitted for heart failure to a general hospital. Rev Esp Cardiol 2002;55:571-578.
6. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart 2003;89:615-620.
7. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986-1995. Circulation 2000;102:1126-1131.
8. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital discharge registry 1988 to 2000. Eur Heart J 2004;25:300-307.
9. Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004;116: 581-589.
10. Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J 2003;146:258-264.
11. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. CHARM Investigators and Committees. Effects of candersartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776.
12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM - Overall programme. Lancet 2003;362:759-766.
13. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D. SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitors enalapril on the long term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-438.
14. Flather M, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long term ACE-inhibitor therapy in patients with heart failure of left ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet 2000;355:1575-1581.
15. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
16. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
17. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
18. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002;39:138-141.
19. Hogg K, Swedberg K, McMurray JJ. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004;43:317-327.
20. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25:1214-1220.
21. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-1955.
22. Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 2002;144:365-372.
23. Martinez-Selles M, Garcia Robles J, Prieto L, Frades E, Munoz R, Diaz Castro O, Almendral J. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function. Rev Esp Cardiol 2002;55:579-586.
24. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001;88:530-533.
25. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community. A study of all incident cases in Olmsted Country, Minnesota in 1991. Circulation 1998;98:2282-2289.
26. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction: long term prognosis. Heart 2005;91:489-494.
27. Maggioni AP, Sinagra G, Opasisch C, Geraci E, Gorini M, Gronda E, Lucci D, Tognoni G, Balli E, Tavazzi L. Beta blockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta-adrenergic blockade beyond controlled clinical trials: the BRING UP experience. Heart 2003;89:299-305.
28. Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, La Rovere M, Ferrari M, Lenta F, Baldin S, Vaccarini C, Gnemmi M, Pinna G, Maestri R, Abelli P, Verdirosi S, Cobelli F. Cost/utility ratio in chronic heart failure: a comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol 2002;40:1259-1266.
29. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004;351:1097-1105.
30. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
31. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781.
32. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, Kalman J, Phillips RA, Steingart R, Brown EJ Jr, Berkowitz R, Moskowitz R, Soni A, Mancini D, Bijou R, Sehhat K, Varshneya N, Kukin M, Katz SD, Sleeper LA, Le Jemtel TH. New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction. J Am Coll Cardiol 2004;43:1432-1438.